Resmetirom: Finally, the Light at the End of the NASH Tunnel?

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?2020 · 85 citations
2. 2Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?2011 · 10 citations
3. 3Editorial: Resmetirom – a promising treatment option for <scp>NASH</scp> and liver fibrosis2023 · 5 citations
4. 4The independent predictors of non‐alcoholic steatohepatitis and its individual histological features.2016 · 157 citations
5. 5Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist #2008 · 209 citations